CN Patent

CN1114613C — 蛋白质溶液的铝/铁处理和膜浓缩方法

Assigned to Novozymes AS · Expires 2003-07-16 · 23y expired

What this patent protects

本发明涉及一种纯化从含水蛋白质溶液中获得的蛋白质的方法，该方法包括：(a)在pH值4-9之间，用可溶性的铁和/或铝化合物处理所说的蛋白质溶液；(b)用一种或多种絮凝剂处理所说的蛋白质溶液；(c)澄清所说的蛋白质溶液；和(d)膜浓缩所说的蛋白质溶液。

USPTO Abstract

本发明涉及一种纯化从含水蛋白质溶液中获得的蛋白质的方法，该方法包括：(a)在pH值4-9之间，用可溶性的铁和/或铝化合物处理所说的蛋白质溶液；(b)用一种或多种絮凝剂处理所说的蛋白质溶液；(c)澄清所说的蛋白质溶液；和(d)膜浓缩所说的蛋白质溶液。

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

Patent Metadata

Patent number: CN1114613C
Jurisdiction: CN
Classification: —
Expires: 2003-07-16
Drug substance claim: No
Drug product claim: No
Assignee: Novozymes AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.